{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:33:33Z","timestamp":1756384413779},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.jgar.2016.06.005","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T12:44:44Z","timestamp":1469537084000},"page":"1-7","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate + emtricitabine-containing HAART both in vivo and in vitro"],"prefix":"10.1016","volume":"7","author":[{"given":"Claudia","family":"Alteri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Surdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Velia Chiara","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola","family":"Di Santo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giosu\u00e8","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Parrotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Mercedes","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Fedele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Carta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Continenza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmela","family":"Pinnetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Bellagamba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Liuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Orchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Latini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ada","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Alcaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Petrosillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Andreoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella d\u2019Arminio","family":"Monforte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Artese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo Federico","family":"Perno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Svicher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2016.06.005_bib0130","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jama.2014.8722","article-title":"International Antiviral Society-USA Panel. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel","volume":"312","author":"G\u00fcnthard","year":"2014","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jgar.2016.06.005_bib0135","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3851\/IMP2287","article-title":"Persistence of novel first-line antiretroviral regimes in a cohort of HIV-positive subjects, CoRIS 2008\u20132010","volume":"18","author":"Jarrin","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jgar.2016.06.005_bib0140","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1086\/521678","article-title":"Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients","volume":"196","author":"Ceccherini-Silberstein","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2016.06.005_bib0145","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1177\/135965350601100609","article-title":"Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine","volume":"11","author":"Marcelin","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jgar.2016.06.005_bib0150","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00002030-200001070-00004","article-title":"Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy","volume":"14","author":"Precious","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2016.06.005_bib0155","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1093\/jac\/dkt173","article-title":"Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir\/ritonavir-containing regimen","volume":"68","author":"Alteri","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2016.06.005_bib0160","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2015.04.014","article-title":"Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance","volume":"119","author":"Hachiya","year":"2015","journal-title":"Antivir Res"},{"key":"10.1016\/j.jgar.2016.06.005_bib0165","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1097\/QAD.0b013e32834d0c20","article-title":"Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection","volume":"25","author":"Haubrich","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2016.06.005_bib0170","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/QAD.0b013e3280121ac6","article-title":"Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients","volume":"21","author":"Metzner","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2016.06.005_bib0175","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/cid\/cir526","article-title":"Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy","volume":"53","author":"Mugavero","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2016.06.005_bib0180","first-page":"642","article-title":"Update of the drug resistance mutations in HIV-1: July 2014","volume":"22","author":"Wensing","year":"2014","journal-title":"Top Antivir Med"},{"issue":"Suppl. 1","key":"10.1016\/j.jgar.2016.06.005_bib0185","first-page":"77","article-title":"Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial","volume":"16","author":"Baxter","year":"2014","journal-title":"HIV Med"},{"key":"10.1016\/j.jgar.2016.06.005_bib0190","doi-asserted-by":"crossref","first-page":"F11","DOI":"10.1097\/01.aids.0000131394.76221.02","article-title":"Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure","volume":"18","author":"Ceccherini-Silberstein","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2016.06.005_bib0195","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1310\/hct1003-160","article-title":"Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir\/tenofovir\/emtricitabine regimen from 200mg to 100mg once daily (TELEX II)","volume":"10","author":"Parks","year":"2009","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.jgar.2016.06.005_bib0200","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/QAI.0b013e3182829bd0","article-title":"Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention","volume":"62","author":"Jackson","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2016.06.005_bib0205","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/135965359900400205","article-title":"In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA","volume":"4","author":"Wainberg","year":"1999","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jgar.2016.06.005_bib0210","doi-asserted-by":"crossref","first-page":"27037","DOI":"10.1016\/S0021-9258(19)61477-8","article-title":"Differential influence of nucleoside analog-resistance mutations K65R and L74V on the overall mutation rate and error specificity of human immunodeficiency virus type 1 reverse transcriptase","volume":"275","author":"Shah","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jgar.2016.06.005_bib0215","doi-asserted-by":"crossref","first-page":"25489","DOI":"10.1074\/jbc.M313534200","article-title":"A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions","volume":"279","author":"Deval","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jgar.2016.06.005_bib0220","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1128\/JVI.01968-08","article-title":"The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs","volume":"83","author":"Ambrose","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.jgar.2016.06.005_bib0225","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAI.0000000000000618","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate in the first protease inhibitor-based single tablet regimen for initial HIV-1 therapy: a randomized phase 2 study","volume":"69","author":"Mills","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2016.06.005_bib0230","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1089\/08892220050042765","article-title":"Presence of 2\u2032,5\u2032-bis-O-(tert-butyldimethylsilyl)-3\u2032-spiro-5\u2033-(4\u2033-amino-1\u2033,2\u2033-oxathiole-2\u2033,2\u2033-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients","volume":"16","author":"Van Laethem","year":"2000","journal-title":"AIDS Res Hum Retrovir"},{"key":"10.1016\/j.jgar.2016.06.005_bib0235","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1097\/QAD.0b013e3283636179","article-title":"The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults","volume":"27","author":"Mackie","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2016.06.005_bib0240","doi-asserted-by":"crossref","first-page":"7186","DOI":"10.1128\/JVI.02084-05","article-title":"Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors","volume":"80","author":"Svicher","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.jgar.2016.06.005_bib0245","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/cmdc.201100362","article-title":"Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine","volume":"6","author":"Alcaro","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jgar.2016.06.005_bib0250","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2174\/092986710790192695","article-title":"Computational analysis of human immunodeficiency virus (HIV) type-1 reverse transcriptase crystallographic models based on significant conserved residues found in highly active antiretroviral therapy (HAART)-treated patients","volume":"17","author":"Alcaro","year":"2010","journal-title":"Curr Med Chem"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716516300613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716516300613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T05:51:49Z","timestamp":1668837109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716516300613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":25,"alternative-id":["S2213716516300613"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2016.06.005","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2016.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}